TY - JOUR AU - Wen, Tianfu AU - Jin, Chen AU - Facciorusso, Antonio AU - Donadon, Matteo AU - Han, Ho-Seong AU - Mao, Yilei AU - Dai, Chaoliu AU - Cheng, Shuqun AU - Zhang, Bixiang AU - Peng, Baogang AU - Du, Shunda AU - Jia, Changjun AU - Xu, Feng AU - Shi, Jie AU - Sun, Juxian AU - Zhu, Peng AU - Nara, Satoshi AU - Millis, J. Michael AU - West China Hospital, MDT of PY - 2018 TI - Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus JF - Hepatobiliary Surgery and Nutrition; Vol 7, No 5 (October 01, 2018): Hepatobiliary Surgery and Nutrition Y2 - 2018 KW - N2 - Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40–70% patients eventually suffer from postoperative recurrence within 5 years. HCC recurrence after surgery severely affects prognosis of the patients. Nevertheless, there is an opportunity to improve patients’ prognosis if doctors and researchers can recognize the importance of a standardized perioperative management and study it in clinical and pre-clinical settings. Hence, based on our own experience and published studies from other researchers, we develop this consensus regarding multidisciplinary management of locally recurrent and metastatic hepatocellular carcinoma after resection. This consensus consists of the entire course of recurrent hepatocellular carcinoma (RHCC) management, including prediction of recurrence, prevention, diagnosis, treatment and surveillance of RHCC. Consensus recommendations are presented with grades of evidences (Ia, Ib, IIa, IIb, III and IV), and strength of recommendations (A, B, C, D and E). We also develop a decision-making path for RHCC treatment, which can intuitively demonstrate the management for RHCC. It is hoped that we may make some effort to standardize the management of RHCC and ultimately understand how to improve outcomes. UR - https://hbsn.amegroups.org/article/view/21312